Umeå University, Department of Medical Biochemistry and Biophysics, Linneaus väg 4, Umeå, SE 90187, Sweden.
Umeå University, Umeå Core Facility for Electron Microscopy (UCEM), Linneaus väg 4, Umeå, SE 90187, Sweden.
J Mol Biol. 2018 Jun 22;430(13):1940-1949. doi: 10.1016/j.jmb.2018.05.001. Epub 2018 May 9.
Fibril formation of the amyloid-β peptide (Aβ) follows a nucleation-dependent polymerization process and is associated with Alzheimer's disease. Several different lengths of Aβ are observed in vivo, but Aβ1-40 and Aβ1-42 are the dominant forms. The fibril architectures of Aβ1-40 and Aβ1-42 differ and Aβ1-42 assemblies are generally considered more pathogenic. We show here that monomeric Aβ1-42 can be cross-templated and incorporated into the ends of Aβ1-40 fibrils, while incorporation of Aβ1-40 monomers into Aβ1-42 fibrils is very poor. We also show that via cross-templating incorporated Aβ monomers acquire the properties of the parental fibrils. The suppressed ability of Aβ1-40 to incorporate into the ends of Aβ1-42 fibrils and the capacity of Aβ1-42 monomers to adopt the properties of Aβ1-40 fibrils may thus represent two mechanisms reducing the total load of fibrils having the intrinsic, and possibly pathogenic, features of Aβ1-42 fibrils in vivo. We also show that the transfer of fibrillar properties is restricted to fibril-end templating and does not apply to cross-nucleation via the recently described path of surface-catalyzed secondary nucleation, which instead generates similar structures to those acquired via de novo primary nucleation in the absence of catalyzing seeds. Taken together these results uncover an intrinsic barrier that prevents Aβ1-40 from adopting the fibrillar properties of Aβ1-42 and exposes that the transfer of properties between amyloid-β fibrils are determined by their path of formation.
淀粉样β肽(Aβ)的纤维形成遵循成核依赖性聚合过程,与阿尔茨海默病有关。体内观察到几种不同长度的 Aβ,但 Aβ1-40 和 Aβ1-42 是主要形式。Aβ1-40 和 Aβ1-42 的纤维结构不同,Aβ1-42 组装体通常被认为更具致病性。我们在这里表明,单体 Aβ1-42 可以被交叉模板化并掺入 Aβ1-40 纤维的末端,而 Aβ1-40 单体掺入 Aβ1-42 纤维则非常差。我们还表明,通过交叉模板化掺入的 Aβ单体获得了亲本纤维的特性。Aβ1-40 掺入 Aβ1-42 纤维末端的能力受到抑制,以及 Aβ1-42 单体采用 Aβ1-40 纤维特性的能力,可能代表了两种机制,减少了体内具有 Aβ1-42 纤维固有和可能致病性特征的纤维总负荷。我们还表明,纤维特性的转移仅限于纤维末端模板化,不适用于最近描述的表面催化二次成核途径的交叉成核,该途径产生的结构与在没有催化种子的情况下通过从头初级成核获得的结构相似。总之,这些结果揭示了一种内在障碍,阻止 Aβ1-40 采用 Aβ1-42 的纤维特性,并暴露了淀粉样β纤维之间的特性转移取决于它们的形成途径。